IFI16 is a Periodontitis Modulating Protein

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03513497

Acronym

IFI

Enrollment

Registered

2018-05-01

Start date

2018-10-18

Completion date

2023-06-28

Last updated

2024-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Inflammatory Response, Severe Periodontitis

Keywords

Teeth, Periodontal disease, acute inflammatory response, stent-induced biofilm overgrowth, periodontal pathogens

Brief summary

To characterize the expression of Interferon gamma inducible protein 16 (IFI16) and Absent in melanoma 2 (AIM2) in gingival tissues in an inflammatory response using an acrylic mouthguard (also referred to as a stent) induced bacteria overgrowth method. Participants: A maximum of 72 Adult subjects will be recruited from the patients, students and staff at the University of North Carolina, as well as the general population in or near Chapel Hill NC. Procedures (methods): Medical history, demographics, (height/weight), urine based pregnancy test, vital signs (to include blood pressures, and pulse) standard dental clinical measures (to include plaque index, gingival index, bleeding on probing, and clinical attachment level), alginate impressions taken for fabrication of an acrylic stent (mouthguard), 2 gingival biopsies, 2 subgingival (below the gumline) plaque samples, and Scaling Root planing (SRP)/or adult prophylaxis

Detailed description

A total of 72 subjects will be enrolled. Specifically, a sufficient number of adults 18 years and older will be screened until 36 healthy (PPC-A) subjects and 36 subjects with severe periodontal disease (PPC-G) will be enrolled. Eligibility for study participation will be determined during the screening session. Barring dropout, subject participation will include 1 to 8 visits lasting over a maximum period of 42 days. The last 3 visits (visit 5-8) will depend on the individual need of the subject for providing SRP. Clinical data and medical history data will be collected at the screening visit to ascertain eligibility. All subjects will have dental plaque and a gingival biopsy collected at baseline. Enrolled subjects will be included in an experimental gingivitis model Stent-Induced Biofilm Overgrowth (SIBO) for 21 days. Individuals will return for safety checks every week during the 21-day period. At 21-days, plaque samples and a gingival biopsy will be collected. For diseased individuals SRP will initiate during the 21-day visit at the SIBO quadrant. Visit 6 (28 days) will include the post-biopsy follow up, prophylaxis (for healthy individuals) and SRP (diseased individuals). Subjects receiving SRP may have 2 additional visits (visit 7 at day 35 and visit 8 at day 42) for completing the SRP of all quadrants and will be dependent on individual need. Medical histories, demographics, height and weight, clinical and biological data described above will be recorded and stored on a secure server located at the University of North Carolina. Each participant enrolled into the study will have a unique identification number that has been stripped of any information that could be used by non-study members to identify the subject.

Interventions

OTHERCustomized acrylic mouthguard

Customized acrylic mouthguards extended to cover approximately 2 mm over gingival margins will be fabricated for each subject. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will cover the area in one sextant where no brushing and flossing teeth is to occur for 21 days.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Subjects must have read, understood and signed an informed consent form. * Subjects must be able and willing to follow study procedures and instructions. * Subjects must be adult males or females with a minimum of 18 years (inclusive). * Subjects must present with at least 20 teeth in the functional dentition, excluding third molars. * Subjects must have at least 3 teeth in each posterior sextant * Subjects must be in good general health * Subjects must be in the healthy (PPC-A) or severe periodontitis (PPC-G) categories according to the PPC (1)

Exclusion criteria

* If the sextants identified for the analysis has implants * All individuals who meet criteria for anti-infective prophylaxis prior to dental procedures * Chronic disease with oral manifestations including diabetes mellitus. * Current smoker or one that has stopped smoking less than 2 years prior to enrollment. * Gross oral pathology other than the periodontal disease. * Treatment with antibiotics for any medical or dental condition within 1 month prior to the screening examination. * Chronic treatment (i.e., two weeks or more) with any medication known to affect periodontal status (e.g., phenytoin, calcium antagonists, cyclosporin, coumadin, non-steroidal anti-inflammatory drugs, aspirin) within one month of the screening examination. * Ongoing medications initiated less than three months prior to enrollment (i.e., medications for chronic medical conditions must be initiated at least three months prior to enrollment). * Significant organ disease including impaired renal function, heart murmur, history of rheumatic fever or valvular disease, or any bleeding disorder. * Individuals with prosthetic material used for intra-cardiac repair (e.g. for congenital heart disease), or intra-cardiac devices, cardiac transplant, infective endocarditis and individuals who have had previous infectious complications of prosthetic joint infections * Infectious diseases such as hepatitis, HIV or tuberculosis. * Anemia or other blood dyscrasias. * Anticoagulant therapy or drugs, such as heparin or warfarin. * Severe unrestored caries, or any condition that is likely to require antibiotic treatment over the trial. * Pregnant, or expect to become pregnant within the next several months. * Females of child-bearing capacity must be willing to have pregnancy test to confirm they are not pregnant. * Females of child-bearing capacity not using any form of contraceptive methods * Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.

Design outcomes

Primary

Measure	Time frame	Description
Change in Absent in Melanoma 2 (AIM2) mRNA Expression Levels	Baseline (Day 0), Visit 5 (Day 21)	Gingival tissues derived from study participants were evaluated for AIM2 mRNA expression at baseline (experimental timepoint named Day 0) and at 21 days (experimental timepoint named Day 21). Gene expression was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and quantified by the delta-delta-CT method.
Change in Interferon Gamma Inducible Protein 16 (IFI16) mRNA Expression Levels	Baseline (Day 0), Visit 5 (Day 21)	Gingival tissues derived from study participants were evaluated for IFI16 mRNA expression at baseline (experimental timepoint named Day 0) and at 21 days (experimental timepoint named Day 21). Gene expression was evaluated by qRT-PCR and quantified by the delta-delta-CT method.
Change in the Percentage of AIM2 Positive Cells	Baseline (Day 0), Visit 5 (Day 21)	Gingival tissues derived from study participants were evaluated for AIM2 immunohistochemical staining at baseline (experimental timepoint named Day 0) and at 21 days (experimental timepoint named Day 21). Cell positivity at baseline and Day 21 was measured by H-score, which consists of (percent low positive cells x 1) + (percent positive cells x 2) + (percent high positive cells x 3).
Change in Percentage of Interferon Gamma Inducible Protein 16 (IFI16) Positive Cells	Baseline (Day 0), Visit 5 (Day 21)	Gingival tissues derived from study participants were evaluated for IFI16 immunohistochemical staining at baseline (experimental timepoint named Day 0) and at 21 days (experimental timepoint named Day 21). Cell positivity at baseline and Day 21 was measured by H-score, which consists of (percent low positive cells x 1) + (percent positive cells x 2) + (percent high positive cells x 3).

Secondary

Measure	Time frame	Description
Correlation of Changes in Periodontal Pathogens With Changes of AIM2	Baseline (Day 0), Visit 5 (Day 21)	Correlation between temporal changes in periodontal pathogen levels that are statistically significant between Day 0 and Day 21 were correlated with temporal changes in AIM2 expression using Spearman rank correlation coefficients and corresponding 95% confidence intervals.
Correlation of Changes in Periodontal Pathogens With Changes of IFI16	Baseline (Day 0), Visit 5 (Day 21)	Correlation between temporal changes in periodontal pathogen levels that are statistically significant between Day 0 and Day 21 were correlated with temporal changes in IFI16 expression using Spearman rank correlation coefficients and corresponding 95% confidence intervals.

Countries

United States

Participant flow

Participants by arm

Arm	Count
Periodontal Profile Class (PPC-A/PPC-B) Periodontally healthy participants (PPC-A) and mild disease (PPC-B) will wear customized acrylic mouthguard only during tooth brushing for 21 days. Customized acrylic mouthguard: Customized acrylic mouthguards extended to cover approximately 2 mm over gingival margins will be fabricated for each subject. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will cover the area in one sextant where no brushing and flossing teeth is to occur for 21 days.	36
Periodontal Profile Class (PPC-G/PPC-E) Participants with severe periodontal disease (PPC-G) and posterior disease (PPC-E) will wear customized acrylic mouthguard only during tooth brushing for 21 days. Customized acrylic mouthguard: Customized acrylic mouthguards extended to cover approximately 2 mm over gingival margins will be fabricated for each subject. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will cover the area in one sextant where no brushing and flossing teeth is to occur for 21 days.	33
Total	69

Baseline characteristics

Characteristic	Periodontal Profile Class (PPC-A/PPC-B)	Total	Periodontal Profile Class (PPC-G/PPC-E)
Age, Continuous	32.0 years STANDARD_DEVIATION 12.5	36.9 years STANDARD_DEVIATION 12.8	42.3 years STANDARD_DEVIATION 10.6
Ethnicity (NIH/OMB) Hispanic or Latino	3 Participants	26 Participants	23 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	33 Participants	43 Participants	10 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	1 Participants	1 Participants	0 Participants
Race (NIH/OMB) Asian	4 Participants	6 Participants	2 Participants
Race (NIH/OMB) Black or African American	4 Participants	8 Participants	4 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	1 Participants	1 Participants
Race (NIH/OMB) Unknown or Not Reported	2 Participants	16 Participants	14 Participants
Race (NIH/OMB) White	25 Participants	37 Participants	12 Participants
Region of Enrollment United States	36 Participants	69 Participants	33 Participants
Sex: Female, Male Female	23 Participants	37 Participants	14 Participants
Sex: Female, Male Male	13 Participants	32 Participants	19 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	0 / 36	0 / 33
other Total, other adverse events	0 / 36	0 / 33
serious Total, serious adverse events	0 / 36	0 / 33

Outcome results

Primary

Change in Absent in Melanoma 2 (AIM2) mRNA Expression Levels

Gingival tissues derived from study participants were evaluated for AIM2 mRNA expression at baseline (experimental timepoint named Day 0) and at 21 days (experimental timepoint named Day 21). Gene expression was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and quantified by the delta-delta-CT method.